<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Clinical nephrology</journal-id><journal-title-group><journal-title xml:lang="en">Clinical nephrology</journal-title><trans-title-group xml:lang="ru"><trans-title>Клиническая нефрология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-3594</issn><issn publication-format="electronic">2414-9322</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">679916</article-id><article-id pub-id-type="doi">10.18565/nephrology.2024.4.17-22</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Prospects for using the QRISK3 risk scale in patients with chronic kidney disease and sarcopenia</article-title><trans-title-group xml:lang="ru"><trans-title>Перспективы использования шкалы риска QRISK3 у пациентов с хронической болезнью почек и саркопенией</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sokolova</surname><given-names>Anna V.</given-names></name><name xml:lang="ru"><surname>Соколова</surname><given-names>Анна Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD in Medicine, Associate Professor, Associate Professor at the Department of Propaedeutics of Internal Diseases No. 1, Institute of Clinical Medicine</p></bio><bio xml:lang="ru"><p>к.м.н., доцент, доцент кафедры пропедевтики внутренних болезней № 1 ИКМ</p></bio><email>sokolova2211@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Stafeeva</surname><given-names>Elena A.</given-names></name><name xml:lang="ru"><surname>Стафеева</surname><given-names>Елена Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD in Medicine, Teaching Assistant at the Department of Propaedeutics of Internal Medicine No. 1, Institute of Clinical Medicine</p></bio><bio xml:lang="ru"><p>к.м.н., ассистент кафедры пропедевтики внутренних болезней № 1 ИКМ</p></bio><email>alena.stafeeva16@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Stafeev</surname><given-names>Aleksandr N.</given-names></name><name xml:lang="ru"><surname>Стафеев</surname><given-names>Александр Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Teaching Assistant at the Department of Hospital Therapy No. 2</p></bio><bio xml:lang="ru"><p>ассистент кафедры госпитальной терапии № 2</p></bio><email>i@stafeev-pro.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dragunov</surname><given-names>Dmitry O.</given-names></name><name xml:lang="ru"><surname>Драгунов</surname><given-names>Дмитрий Олегович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD in Medicine, Associate Professor, Associate Professor at the Department of Propaedeutics of Internal Diseases No. 1, Institute of Clinical Medicine</p></bio><bio xml:lang="ru"><p>к.м.н., доцент, доцент кафедры пропедевтики внутренних болезней № 1 ИКМ</p></bio><email>tamops2211@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Arutyunov</surname><given-names>Grigory P.</given-names></name><name xml:lang="ru"><surname>Арутюнов</surname><given-names>Григорий Павлович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr.Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Director of the Institute of Clinical Medicine, Head of the Department of Propaedeutics of Internal Diseases No. 1, Institute of Clinical Medicine</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, чл.-корр. РАН, директор Института клинической медицины, заведующий кафедрой пропедевтики внутренних болезней № 1 ИКМ</p></bio><email>arutyunov_gp@rsmu.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Pirogov Russian National Research Medical University</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РФ</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Research Institute for Healthcare Organization and Medical Management</institution></aff><aff><institution xml:lang="ru">ГБУ «Научно-исследовательский институт организации здравоохранения и медицинского менеджмента» ДЗМ</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава РФ (Сеченовский университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-12-08" publication-format="electronic"><day>08</day><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>17</fpage><lpage>22</lpage><history><date date-type="received" iso-8601-date="2025-05-19"><day>19</day><month>05</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-05-19"><day>19</day><month>05</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, ООО «Бионика Медиа»</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/2075-3594/article/view/679916">https://journals.eco-vector.com/2075-3594/article/view/679916</self-uri><abstract xml:lang="en"><p><bold>Objective. </bold>Evaluation of the relationship between sarcopenia, chronic kidney disease (CKD) and the risk of cardiovascular events according to the QRISK3 scale.</p> <p><bold>Material and methods. </bold>The study involved 143 patients with CKD, including 40 with sarcopenia and 104 without sarcopenia. All patients had their skeletal muscle mass index calculated, muscle strength assessed, their SPPB score calculated and their risk assessed according to the QRISK3 scale. For statistical analysis of the data obtained, the R language, RStudio software, with the following packages were used: tidyverse, gt, modelsummary, ggplot2. At a significance level (p) of less than 0.05, the null hypothesis (H0) was rejected, and changes between the groups were considered reliable.</p> <p><bold>Results. </bold>Patients with sarcopenia had a higher probability of developing cardiovascular diseases, according to the QRISK3 scale. Patients with sarcopenia had higher strength index, strength and skeletal muscle mass index, and lower body mass index compared to patients without sarcopenia. Glomerular filtration rate (SFR) and physical fitness, expressed as points on the SPPB scale, were found to have a significant effect on QRISK3. In patients with sarcopenia, a stronger relationship between age and QRISK3 was observed. An increase in SFR by 1 ml/min/1,73 m² was associated with a decrease in QRISK3 by 0,49%, and the presence of sarcopenia and male gender strengthened this relationship.</p> <p><bold>Conclusion. T</bold>he obtained results indicate that kidney function and sarcopenia can significantly affect the assessment of cardiovascular risk according to the QRISK3 scale.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель исследования.</bold> Изучение взаимосвязи между саркопенией, хронической болезнью почек (ХБП) и риском сердечно-сосудистых событий по шкале QRISK3.</p> <p><bold>Материал и методы. </bold>В исследовании приняли участие 143 пациента с ХБП, из них 40 человек – с саркопенией и 104 человека – без саркопении. У всех пациентов был рассчитан индекс скелетно-мышечной массы, проведена оценка мышечной силы, рассчитан балл по шкале SPPB и оценен риск по шкале QRISK3. Для статистической обработки полученных данных использовали язык R-программное обеспечение RStudio с использование пакетов: tidyverse, gt, modelsummary, ggplot2. При уровне значимости (р) менее 0,05 нулевая гипотеза (H0) отклонялась, и изменения между группами считались достоверными.</p> <p><bold>Результаты. </bold>Пациенты с саркопенией имели более высокую вероятность развития сердечно-сосудистых заболеваний, согласно градации QRISK3. У пациентов с саркопенией были выявлены более высокие показатели силового индекса, силы и индекса скелетно-мышечной массы, а также более низкие значения индекса массы тела по сравнению с пациентами без саркопении. Установлено, что скорость клубочковой фильтрации (СКФ) и физическое состояние, выраженное в баллах по шкале SPPB, оказывают значимое влияние на QRISK3. У пациентов с саркопенией наблюдалась более сильная связь между возрастом и QRISK3. Увеличение СКФ на 1 мл/мин/1,73 м² связано со снижением QRISK3 на 0,49%, а наличие саркопении и мужской пол усиливают эту взаимосвязь.</p> <p><bold>Заключение. </bold>Полученные результаты указывают на то, что функция почек и саркопения могут существенно влиять на оценку риска сердечно-сосудистых заболеваний по шкале QRISK3.</p></trans-abstract><kwd-group xml:lang="en"><kwd>QRISK</kwd><kwd>chronic kidney disease</kwd><kwd>glomerular filtration rate</kwd><kwd>sarcopenia</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>QRISK</kwd><kwd>хроническая болезнь почек</kwd><kwd>скорость клубочковой фильтрации</kwd><kwd>саркопения</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Graham I.M., Di Angelantonio E., Visseren F., et al. European Society of Cardiology Cardiovascular Risk Collaboration. Systematic Coronary Risk Evaluation (SCORE): JACC Focus Seminar 4/8. J. Am. Coll. Cardiol. 2021;77(24):3046–57. Doi: 10.1016/j.jacc.2021.04.052. [PMID: 34140109, PMCID: PMC8091419].</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Gansevoort R.T., Correa-Rotter R., Hemmelgarn B.R., et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–52. Doi: 10.1016/S0140-6736(13)60595-4. [Epub 2013 May 310.qwa, PMID: 23727170].</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Li X., Lindholm B. Cardiovascular Risk Prediction in Chronic Kidney Disease. Am. J. Nephrol. 2022;53(10):730–9. Doi: 10.1159/000528560. [Epub 2022 Dec 8, PMID: 36481730].</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Mok Y., Ballew S.H., Matsushita K. Chronic kidney disease measures for cardiovascular risk prediction. Atherosclerosis. 2021;335:110–8. Doi: 10.1016/j.atherosclerosis.2021.09.007. [Epub 2021 Sep 9, PMID: 34556333].</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Jankowski J., Floege J., Fliser D., et al. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021;143(11):1157–72. Doi: 10.1161/CIRCULATIONAHA.120.050686. [Epub 2021 Mar 15, PMID: 33720773, PMCID: PMC7969169].</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Castillo E.M., Goodman-Gruen D., Kritz-Silverstein D., et al. Sarcopenia in elderly men and women: the Rancho Bernardo study. Am. J. Prev. Med. 2003;25(3):226–31.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Гасанов М.З. Саркопения у пациентов с хронической болезнью почек: распространенность, особенности патогенеза и клиническое значение. Нефрология. 2021;25(1):47–58. Doi: 10.36485/1561-6274-2021-25-1-47-58.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Wilkinson T.J., Miksza J., Yates T., et al. Association of sarcopenia with mortality and end-stage renal disease in those with chronic kidney disease: a UK Biobank study. J Cachexia Sarcopen Muscle. 2021;12(3):586–98. Doi: 10.1002/jcsm.12705.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Cruz-Jentoft A.J., Bahat G., Bauer J., et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. Doi: 10.1093/ageing/afy169. Erratum in: Age Ageing. [PMID: 30312372, PMCID: PMC 6322506].</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kidney International Supplements. KDIGO 2019;48(4):601. 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. ScienceDirect.com [Electronic resource]. URL: https://www.sciencedirect.com/journal/kidneyinternational-supplements/vol/3/issue/1.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Hippisley-Cox J., Coupland C., Vinogradova Y., et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335(7611):136. Doi: 10.1136/bmj.39261.471806.55. [Epub 2007 Jul 5, PMID: 17615182, PMCID: PMC1925200].</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Hippisley-Cox J., Coupland C., Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099. Doi: 10.1136/bmj.j2099. [PMID: 28536104, PMCID: PMC5441081].</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Hippisley-Cox J., Coupland C.A.C., Bafadhel M., et al. Development and validation of a new algorithm for improved cardiovascular risk prediction. Nat. Med. 2024;30(5):1440–7. Doi: 10.1038/s41591-024-02905-y. [Epub 2024 Apr 18, PMID: 38637635, PMCID: PMC11108771].</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Damluji A.A., Alfaraidhy M., AlHajri N., et al. Sarcopenia and Cardiovascular Diseases. Circulation. 2023;147(20):1534–53. Doi: 10.1161/CIRCULATIONAHA.123.064071. [Epub 2023 May 15, PMID: 37186680, PMCID: PMC10180053].</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Okamura H., Kimura N., Mieno M., et al. Preoperative sarcopenia is associated with late mortality after off-pump coronary artery bypass grafting. Eur. J. Cardiothorac. Surg. 2020;58(1):121–9. Doi: 10.1093/ejcts/ezz378. [PMID: 31995164].</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Pizzimenti M., Meyer A., Charles A.L., et al. Sarcopenia and peripheral arterial disease: a systematic review. J. Cachexia Sarcopenia Muscle. 2020;11(4):866–86. Doi: 10.1002/jcsm.12587. [Epub 2020 Jul 10, PMID: 32648665, PMCID: PMC7432591].</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Voulgaridou G., Tyrovolas S., Detopoulou P., et al. Diagnostic Criteria and Measurement Techniques of Sarcopenia: A Critical Evaluation of the Up-to-Date Evidence. Nutrients. 2024;16(3):436. Published 2024 Feb 1. Doi: 10.3390/nu16030436.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Kara M., Kaymak B., Frontera W., et al. Diagnosing sarcopenia: Functional perspectives and a new algorithm from the ISarcoPRM. J. Rehabil. Med. 2021;53(6):jrm00209. Published 2021 Jun 21. Doi: 10.2340/16501977-2851.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Zhang Y., Guo J.Y., Wang F., et al. Start with muscle mass or muscle strength in diagnosis and management of sarcopenia? A systematic review of guidance documents. Asia Pac. J. Clin. Nutr. 2024;33(2):247–71. Doi: 10.6133/apjcn.202406_33(2).0011.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Соколова А.В., Драгунов Д.О., Арутюнов Г.П., Митрохин В.М. Прогностическое значение саркопении у пациентов с ХБП. Клиническая нефрология. 2019;1:48–55. [20. Sokolova A.V., Dragunov D.O., Arutyunov G.P., Mitrokhin V.M. Prognostic value of sarcopenia in patients with CKD. Clinical nephrology. 2019;1:48–55 (In Russ.)].</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Соколова А.В, Драгунов Д.О., Арутюнов Г.П. Скрининг на саркопению у пациентов с хронической сердечной недостаточностью и хронической болезнью почек. Клиническая нефрология. 2024;16(1):25–29. [21. Sokolova A.V., Dragunov D.O., Arutyunov G.P. Screening for sarcopenia in patients with chronic heart failure and chronic kidney disease. Clinical nephrology. 2024;16(1):25–29 (In Russ.)].</mixed-citation></ref></ref-list></back></article>
